02235 微泰医疗－Ｂ
按盘价 
7.120 -0.060 (-0.836%) | 日期 | 股东名称 | 披露原因 | 买入／卖出涉及 的股份数目 |
每股平均价 | 持有权益的 股份数目 |
占已发行 股本(%) |
| 26/11/2025 | OrbiMed Advisors V Limited | 1101(L) | +1,450,600(L) | 24,260,100(L) | 14.34 | |
| 26/11/2025 | OrbiMed Asia Partners V, L.P. | 1101(L) | +1,450,600(L) | 24,260,100(L) | 14.34 | |
| 26/11/2025 | OrbiMed Asia GP V, L.P. | 1101(L) | +1,450,600(L) | 24,260,100(L) | 14.34 | |
| 24/11/2025 | 于非 | 1113(L) | +2,269,008(L) | 2,269,008(L) | 1.09 | |
| 24/11/2025 | 刘秀 | 1113(L) | +642,885(L) | 642,885(L) | 0.31 | |
| 24/11/2025 | 杭州研泰投资合夥企业（有限合夥） | 1704(L) | 2,157,409(L) | 1.04 | ||
| 24/11/2025 | 郑攀 | 1213(L) | -10,530,757(L) | 71,478,780(L) | 34.33 | |
| 24/11/2025 | 施永辉 | 1113(L) | +2,123,320(L) | 2,123,320(L) | 1.02 | |
| 19/11/2025 | OrbiMed Asia Partners V, L.P. | 1101(L) | +2,090,000(L) | 22,760,100(L) | 13.45 | |
| 19/11/2025 | 郑攀 | 1201(L) | -2,090,000(L) | HKD6.900(L) | 38,700,719(L) | 22.88 |
| 19/11/2025 | OrbiMed Advisors V Limited | 1101(L) | +2,090,000(L) | 22,760,100(L) | 13.45 | |
| 19/11/2025 | OrbiMed Asia GP V, L.P. | 1101(L) | +2,090,000(L) | 22,760,100(L) | 13.45 | |
| 13/11/2025 | OrbiMed Advisors V Limited | 1101(L) | +900,000(L) | 20,670,100(L) | 12.22 | |
| 13/11/2025 | OrbiMed Asia GP V, L.P. | 1101(L) | +900,000(L) | 20,670,100(L) | 12.22 | |
| 13/11/2025 | OrbiMed Asia Partners V, L.P. | 1101(L) | +900,000(L) | 20,670,100(L) | 12.22 | |
| 13/11/2025 | 郑攀 | 1201(L) | -900,000(L) | HKD6.040(L) | 40,790,719(L) | 24.11 |
| 12/09/2025 | CDBI Partners Fund II, L.P. | 1201(L) | -93,200(L) | HKD8.610(L) | 8,396,831(L) | 4.96 |
| 12/09/2025 | CD Capital Healthcare FUND V, L.P. | 1201(L) | -93,200(L) | HKD8.610(L) | 8,396,831(L) | 4.96 |
| 12/09/2025 | CD Capital GP Ltd | 1201(L) | -93,200(L) | HKD8.610(L) | 8,396,831(L) | 4.96 |
| 12/09/2025 | CDBI Partners Fund I, L.P. | 1201(L) | -93,200(L) | HKD8.610(L) | 8,396,831(L) | 4.96 |
| 12/09/2025 | CDBI GP, Ltd | 1201(L) | -93,200(L) | HKD8.610(L) | 8,396,831(L) | 4.96 |
| 12/09/2025 | CDBI Partners GP, Ltd | 1201(L) | -93,200(L) | HKD8.610(L) | 8,396,831(L) | 4.96 |
| 12/09/2025 | Master Summer Limited | 1201(L) | -93,200(L) | HKD8.610(L) | 8,396,831(L) | 4.96 |
| 16/05/2025 | Qiming Venture Partners V, L.P. | 1201(L) | -6,956,748(L) | 15,190,018(L) | 34.76 | |
| 16/05/2025 | QM32 Limited | 1201(L) | -6,956,748(L) | 15,190,018(L) | 34.76 | |
| 16/05/2025 | Qiming GP V, L.P. | 1201(L) | -6,956,748(L) | 15,190,018(L) | 34.76 | |
| 16/05/2025 | Qiming Corporate GP V, Ltd. | 1201(L) | -6,956,748(L) | 15,190,018(L) | 34.76 | |
| 08/05/2025 | Suzhou Qicheng Investment Management Partnership (Limited Partnership) | 1201(L) | -5,043,252(L) | 11,011,913(L) | 5.29 | |
| 08/05/2025 | 于佳 | 1201(L) | -5,043,252(L) | 11,011,913(L) | 5.29 | |
| 08/05/2025 | Suzhou Qiming Ronghe Venture Capital Partnership (Limited Partnership) | 1201(L) | -5,043,252(L) | 11,011,913(L) | 5.29 | |
| 08/05/2025 | Shanghai Qichang Investment Consulting Co., Ltd. | 1201(L) | -5,043,252(L) | 11,011,913(L) | 5.29 | |
| 08/05/2025 | 胡旭波 | 1201(L) | -5,043,252(L) | 11,011,913(L) | 5.29 | |
| 22/04/2025 | LAV Kecheng Hong Kong Limited | 1001(L) | +3,000,000(L) | 3,000,000(L) | 6.87 | |
| 22/04/2025 | LAV Corporate VI GP Opportunities, Ltd. | 1001(L) | +3,000,000(L) | 3,000,000(L) | 6.87 | |
| 22/04/2025 | LAV Fund VI Opportunities, L.P. | 1001(L) | +3,000,000(L) | 3,000,000(L) | 6.87 | |
| 22/04/2025 | LAV GP VI Opportunities, L.P. | 1001(L) | +3,000,000(L) | 3,000,000(L) | 6.87 | |
| 22/04/2025 | Shanghai Liyao Investment Management Co., Ltd (上海礼曜投资管理有限公司) | 1101(L) | 24,776,804(L) | 11.90 | ||
| 22/04/2025 | 陈飞 | 1101(L) | 24,776,804(L) | 11.90 | ||
| 22/04/2025 | 施毅 | 1101(L) | +3,000,000(L) | 20,091,680(L) | 45.98 | |
| 07/03/2025 | OrbiMed Advisors V Limited | 1101(L) | +4,589,900(L) | HKD4.990(L) | 19,651,800(L) | 11.61 |
| 1 2 | ||||||
| 备注： | (L) - 长仓：包括 (1) 持有股份；(2) 透过持有丶沽出或发行金融合约，有权或有责任购买相关股份。 |
| (S) - 短仓：包括 (1) 借入股份；(2) 透过持有丶沽出或发行金融合约，有权或有责任沽出相关股份。 | |
| (P) - 可供借出的股份 | |
| 即时报价更新时间为 09/12/2025 17:59 | |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |